The Yin and Yang of the Natural Product Triptolide and Its Interactions with XPB, an Essential Protein for Gene Expression and DNA Repair
- PMID: 39457411
- PMCID: PMC11507457
- DOI: 10.3390/genes15101287
The Yin and Yang of the Natural Product Triptolide and Its Interactions with XPB, an Essential Protein for Gene Expression and DNA Repair
Abstract
Triptolide, a bioactive diterpene tri-epoxide extracted from Tripterygium wilfordii Hook F (TWHF), exhibits notable pharmacological activities, including anti-inflammatory, immunosuppressive, antifertility, and anticancer effects. Despite its promising therapeutic potential, clinical applications of triptolide are significantly limited by its poor water solubility and substantial toxicity, particularly hepatotoxicity, nephrotoxicity, and cardiotoxicity. These toxic effects are difficult to separate from many of its desired therapeutic effects, the Yin and Yang of triptolide applications. Triptolide's therapeutic and toxic effects are linked to its inhibitory interactions with XPB, a DNA helicase essential for transcription by RNA polymerase II (RNAPII) and nucleotide excision repair (NER). By irreversibly binding to XPB, triptolide inhibits its ATPase activity, leading to global repression of transcription and impaired NER, which underlies its cytotoxic and antitumor properties. Recent developments, including triptolide prodrugs such as Minnelide and derivatives like glutriptolides, aim to enhance its pharmacokinetic properties and reduce toxicity. This review critically examines triptolide's chemical structure, therapeutic applications, toxicological profile, and molecular interactions with XPB and other protein targets to inform future strategies that maximize therapeutic efficacy while minimizing adverse effects.
Keywords: anticancer drug; autoimmune disease; hepatotoxicity; inflammation; transcription.
Conflict of interest statement
The authors declare no conflicts of interest. The funders had no role in the design of the study; in the writing of the manuscript; or in the decision to publish the results.
Figures





Similar articles
-
XPB, a subunit of TFIIH, is a target of the natural product triptolide.Nat Chem Biol. 2011 Mar;7(3):182-8. doi: 10.1038/nchembio.522. Epub 2011 Jan 30. Nat Chem Biol. 2011. PMID: 21278739 Free PMC article.
-
Triptolide: Medicinal chemistry, chemical biology and clinical progress.Eur J Med Chem. 2019 Aug 15;176:378-392. doi: 10.1016/j.ejmech.2019.05.032. Epub 2019 May 13. Eur J Med Chem. 2019. PMID: 31121546 Review.
-
Triptolide and its expanding multiple pharmacological functions.Int Immunopharmacol. 2011 Mar;11(3):377-83. doi: 10.1016/j.intimp.2011.01.012. Epub 2011 Jan 19. Int Immunopharmacol. 2011. PMID: 21255694 Review.
-
Triptolide and Its Derivatives as Cancer Therapies.Trends Pharmacol Sci. 2019 May;40(5):327-341. doi: 10.1016/j.tips.2019.03.002. Epub 2019 Apr 8. Trends Pharmacol Sci. 2019. PMID: 30975442 Review.
-
Triptolide Induces Cell Killing in Multidrug-Resistant Tumor Cells via CDK7/RPB1 Rather than XPB or p44.Mol Cancer Ther. 2016 Jul;15(7):1495-503. doi: 10.1158/1535-7163.MCT-15-0753. Epub 2016 Mar 29. Mol Cancer Ther. 2016. PMID: 27197304
Cited by
-
Super-enhancers and efficacy of triptolide in small cell carcinoma of the ovary hypercalcemic type.iScience. 2025 Jan 7;28(2):111770. doi: 10.1016/j.isci.2025.111770. eCollection 2025 Feb 21. iScience. 2025. PMID: 39906560 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources